BWXT: NextGen MURR nuclear medicine sub-contract + TD Securities Buy at PT reinforce the nuclear renaissance thesis. 13.2% annual revenue growth + FCF improvement well-documented. After 111% 1-yr surge valuation is stretched but fundamentals deserve 8. Monitoring for entry vs fair value.
Upgrading 8→9. Iran war is the clearest BWXT catalyst possible. Governments globally implementing 1970s-style energy conservation (4-day weeks, AC bans) = accelerated nuclear procurement. Every week of energy crisis is a future BWXT backlog addition. .75B 2026 guidance + .3B backlog already set. This war accelerates that by years. Now our highest-conviction position. Buy on any dip toward $190.
Upgrading 7→8. 2026 guidance of .75B revenue (high-teens growth) + .3B backlog (+50% YoY) = fundamental anchor confirmed. Alkeon Capital +163% stake surge is a strong institutional signal. Federal procurement activity ongoing. Stock at vs our avg — we're underwater but thesis is the strongest it's been. The backlog makes near-term revenue highly visible.
Iran-Israel war + Qatar LNG crisis accelerates energy security narrative. Naval operations in Gulf expand DoD demand for nuclear propulsion. SMR thesis benefiting from LNG crisis driving nuclear urgency in Europe/Asia. Thesis strengthened, holding 7.
Upgrading BWXT 7→8. Q4 backlog +50% to .3B is exceptional — 3+ years of revenue visibility. Alkeon +163% stake is strong institutional signal. TD Cowen initiation expands coverage. All this + ongoing federal procurement. Naval nuclear monopoly with defense modernization tailwind, now with dramatic backlog growth confirming accelerating demand. This is thesis validation, not noise.
Downgraded from 8. Nuclear services/defense company with solid fundamentals and above-200dma. BUT: analyst consensus upside only 12% (below 20% threshold for conv-8), and no valid DCF (stale model at $68 vs $207 price). Conv-8 requires upside ≥20% with at least one supporting data point. Thesis intact — nuclear renaissance secular driver — but price has run ahead.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
33.8%/yr
±4.2% · revenue growth to justify current price
FCF-Based Reverse DCF
41.3%/yr
±4.1% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Naval reactor monopoly is a 40-year cash waterfall — 73% of revenue at 20%+ margins with no competitive threat. Record $7.3B backlog (+50% YoY). TRISO fuel partnership with Kairos positions BWXT as the sole US supplier for the coming SMR fleet. $1.5B NNSA enrichment contract adds another decade-long revenue stream.
Commercial operations (27% of revenue) at only 6.8% margin — improving but still a drag. 43x forward PE is a premium valuation that assumes near-perfect execution on the commercial nuclear ramp. Net debt $1.5B at 3.5x EBITDA limits flexibility if the SMR timeline slips beyond 2030.
NRC regulatory delays beyond 2028, TRISO fuel commoditized by competitor, commercial margins stall below 10%
Updated Mar 11
BWXT joined Burns & McDonnell as sub-contractor for University of Missouri's NextGen MURR research reactor. Stock up 6.3% on the news. TD Securities initiated with Buy and target. Thesis momentum bui...
BWXT added as sub-contractor on U Missouri NextGen MURR research reactor project; TD Securities initiates Buy at PT citing 13.2% annual revenue growth and improving FCF margins. Nuclear momentum buil...
Sole-source naval nuclear propulsion franchise with 70-year moat. 2026 guide: $3.75B revenue, $645-660M EBITDA, 50% backlog growth to $7.3B. EPS growing 11-13% annually. Advanced tech (microreactor, s...
BWXT 2026 guidance confirmed: $3.75B revenue, adjusted EBITDA $645-660M, robust FCF, record backlog. Stock up 111% in 1 year. Federal procurement items tied to BWXT programs continue appearing in Marc...
BWXT confirmed 2026 guidance of .75B revenue and -660M EBITDA, underpinned by record .3B backlog (+50% YoY). Alkeon Capital boosted stake 163%. TD Cowen initiated coverage bullishly. Contract procurem...
BWXT reported Q4 revenue beat and 50% annual backlog surge to .3B. Alkeon Capital acquired 978K additional shares (+163% of position). TD Cowen initiated coverage in March. Federal procurement items c...
Alkeon Capital acquired 978K additional BWXT shares (+163% increase). Follows Q4 revenue beat and 50% YoY backlog surge to .3B. TD Cowen initiated coverage. Strong institutional conviction building ar...
BWXT Q4 earnings beat expectations. Backlog grew 50% YoY to $7.3B — strongest single data point confirming multi-year visibility. TD Cowen initiated coverage. Incremental positive confirmation of 10-K...
FY2025: Revenue +18.3% to $3.2B, backlog +50% to $7.26B, two transformative acquisitions. Margin compression is temporary integration noise. Naval monopoly intact. 0% convertible at $262.51 = manageme...
BWXT opened its Centrifuge Manufacturing Development Facility in Oak Ridge, TN — a milestone toward reestablishing fully domestic uranium enrichment capability. Reinforces defense/energy dual-use thes...
FY2025: Revenue +18.3% to .2B. Backlog surges 50% to .26B. Two major acquisitions (A.O.T, Kinectrics). Issued $1.25B 0% convertible notes. Naval monopoly thesis intact, commercial becoming major growt...
BWXT posted 18% revenue growth to $3.2B and 50% backlog expansion to $7.3B in 2025, driven by naval reactor monopoly (73% revenue, 20%+ margins) and surging commercial nuclear/medical business (63% gr...